• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    5/23/25 4:28:44 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email
    false 0000927066 0000927066 2025-05-23 2025-05-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

    Form 8-K 

     

     

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 23, 2025

     

     

     

     

     

    DAVITA INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware 1-14106 51-0354549
    (State or other jurisdiction
    of incorporation)
    (Commission File Number) (IRS Employer
    Identification No.)

     

    2000 16th Street
    Denver, CO 80202
    (Address of principal executive offices including Zip Code)

     

    (720) 631-2100

    (Registrant’s telephone number, including area code)

     

    Not applicable
    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 240.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class: Trading symbol(s): Name of each exchange on which registered:
    Common Stock, $0.001 par value DVA New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On May 23, 2025 (the “Closing Date”), DaVita Inc. (the “Company”) completed the previously announced private offering (the “Notes Offering”) of $1.0 billion aggregate principal amount of its 6.750% Senior Notes due 2033 (the “2033 Notes”).

     

    The 2033 Notes and related subsidiary guarantees were offered and sold in a private transaction exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), to qualified institutional buyers in accordance with Rule 144A under the Securities Act and to non-U.S. persons outside of the United States pursuant to Regulation S under the Securities Act. The 2033 Notes and related subsidiary guarantees have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and other applicable securities laws.

     

    The Company received total net proceeds from the Notes Offering, after deducting the initial purchasers’ discount and other estimated fees and expenses, of approximately $986 million. The Company intends to use the net proceeds from the Notes Offering (i) to repay outstanding revolving credit facility borrowings in the amount of $830 million, and (ii) to pay any costs, fees and expenses in connection with the foregoing. The Company intends to use the remaining net proceeds for general corporate purposes, including, without limitation, for repurchases of capital stock, working capital and capital expenditures.

     

    Indenture

     

    The terms of the 2033 Notes and related subsidiary guarantees are governed by an indenture, dated as of the Closing Date (the “Indenture”), among the Company, as issuer, certain subsidiaries of the Company, as guarantors (collectively, the “Guarantors”), and Wilmington Trust, National Association, as trustee (in such capacity, the “Trustee”).

     

    Interest and Maturity. The 2033 Notes bear interest at a rate of 6.750% per annum and mature on July 15, 2033. Interest is payable on the 2033 Notes on January 15 and July 15 of each year, commencing on January 15, 2026.

     

    Guarantees. The Company’s obligations under the 2033 Notes and the Indenture are jointly and severally and fully and unconditionally guaranteed by each of the Company’s domestic subsidiaries that guarantee the Company’s obligations under its existing senior secured credit facilities and any future domestic subsidiaries that guarantee indebtedness obligations of the Company or any other Company subsidiary, subject to certain exceptions set forth in the Indenture.

     

    Ranking. The 2033 Notes and related subsidiary guarantees are the unsecured senior obligations of the Company and the Guarantors, respectively, and (i) rank equally in right of payment with all other existing and future senior indebtedness of the Company and the Guarantors; (ii) are effectively subordinated to all existing and future secured indebtedness and secured guarantees of the Company and the Guarantors (including indebtedness and guarantees under the Company’s existing senior secured credit facilities) to the extent of the value of the collateral securing such indebtedness and guarantees; (iii) are structurally subordinated to all existing and future indebtedness, guarantees and other liabilities (including trade payables) of the Company’s subsidiaries that do not guarantee the 2033 Notes; and (iv) are senior in right of payment to all of the Company’s existing and future indebtedness that is, by its terms, expressly subordinated in right of payment to the 2033 Notes.

     

    Covenants. The Indenture contains restrictive covenants that limit the ability of the Company and its Guarantors to, among other things, create certain liens; enter into certain sale/leaseback transactions; or merge with or into, or convey, transfer or lease all or substantially all its assets. These covenants are subject to a number of important exceptions and qualifications as set forth in the Indenture.

     

    Events of Default. The Indenture provides for events of default (subject in certain cases to customary grace and cure periods), which include, among others, nonpayment of principal or interest when due, breach of covenants or other agreements in the Indenture, defaults in payment of certain other indebtedness and certain events of bankruptcy or

     

     

     

     

    insolvency. Generally, if an event of default occurs, the Trustee or the holders of at least 25% in principal amount of the outstanding 2033 Notes may declare the principal of and accrued but unpaid interest on all of the 2033 Notes to be due and payable immediately.

     

    Optional Redemption. At any time prior to July 15, 2028, the Company may redeem the 2033 Notes, in whole or from time to time in part, at a “make-whole” premium as set forth in the Indenture and form of 2033 Notes, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. At any time on or after July 15, 2028, the Company may redeem the 2033 Notes, in whole or from time to time in part at the redemption prices set forth in the Indenture and form of 2033 Notes, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, at any time prior to July 15, 2028, the Company may redeem up to 40% of the original aggregate principal amount of the 2033 Notes with the net cash proceeds of certain equity offerings, as described in the Indenture, at a redemption price equal to 106.750% of the principal amount of the 2033 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. If the Company experiences certain change of control events, the Company must offer to repurchase all of the 2033 Notes (unless otherwise redeemed) at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but excluding, the repurchase date.

     

    No Registration Rights or Listing. The 2033 Notes and related subsidiary guarantees do not have the benefit of any registration or similar rights. The 2033 Notes will not be listed on any securities exchange.

     

    The foregoing descriptions of the Indenture and the 2033 Notes do not purport to be complete and are qualified in their entirety by reference to the actual Indenture and form of 2033 Notes, copies of which are filed as Exhibits 4.1 and 4.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    No.
      Description
         
    4.1   Indenture, dated as of May 23, 2025, by and among DaVita Inc., the subsidiary guarantors party thereto and Wilmington Trust, National Association, as trustee.
    4.2   Form of 6.750% Senior Notes due 2033 (included as Exhibit A to the Indenture filed herewith as Exhibit 4.1).
    104.1   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      DAVITA INC.
         
    Date: May 23, 2025 By: /s/ Joel Ackerman
        Joel Ackerman
        Chief Financial Officer and Treasurer

     

     

    Get the next $DVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    10/29/2021$113.00 → $111.00Sector Perform
    RBC Capital
    More analyst ratings

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates

      DENVER, May 30, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care company, issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation (CMMI) related to its Kidney Care Choices (KCC) Model. It can be attributed to Misha Palecek, chief transformation officer for DaVita. "As a dedicated participant in the government's value-based care initiative and a pioneer in this field for the last twenty years, we applaud CMMI's decision to extend the Kidney Care Choices (KCC) Model for an additional year. We believe the investments made by CMMI and participants alike will result in long-term savings in the upcoming years. The program's emph

      5/30/25 2:35:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Releases Annual Community Care Report, Highlights Achievements in Corporate Citizenship

      Captures key initiatives achieved in 2024, driving 2025 ESG goals DENVER, May 20, 2025 /PRNewswire/ -- Today, DaVita (NYSE:DVA) published its Community Care report, underpinning its long-standing commitment to corporate citizenship and highlighting strides made towards ambitious Environmental, Social and Governance (ESG) goals set to be achieved this year. Milestones and achievements reflect calendar year 2024. In 2021, DaVita announced broadened ESG goals and has since reported progress against its five strategic focus areas: Patient Care, Teammate Engagement, Environmental Stewardship, Healthy Communities and Leading with Integrity and Accountability. "This year, we're celebrating 25 years

      5/20/25 9:05:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. 1st Quarter 2025 Results

      DENVER, May 12, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2025. "Our strong first quarter performance demonstrates the stability and consistency of our operating model" said Javier Rodriguez, CEO of DaVita Inc. "We maintain a steadfast commitment to being the provider, employer and partner of choice and returning value to our shareholders." Financial and operating highlights for the quarter ended March 31, 2025: Consolidated revenues were $3.224 billion.Operating income was $439 million.Diluted earnings per share was $2.00.Operating cash flow was $180 million and free cash flow was $(45) million.Repurchased 3.7 milli

      5/12/25 4:05:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

      SC 13G/A - DAVITA INC. (0000927066) (Subject)

      2/13/24 5:02:42 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

      SC 13G/A - DAVITA INC. (0000927066) (Subject)

      2/9/22 3:43:35 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

      SC 13D/A - DAVITA INC. (0000927066) (Subject)

      8/4/21 4:02:59 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Moore Gregory J. was granted 348 shares, increasing direct ownership by 6% to 6,451 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      5/16/25 9:15:16 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • Director Berg Charles was granted 348 shares, increasing direct ownership by 2% to 19,982 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      5/16/25 9:15:04 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • Director Yale Phyllis R was granted 348 shares, increasing direct ownership by 3% to 13,201 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      5/16/25 9:14:55 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    See more
    • DaVita Appoints Jessica Hergenreter as Chief People Officer

      DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

      10/17/24 1:00:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

      DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

      9/13/24 8:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Appoints New Chief Information Officer

      Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

      5/13/24 9:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on DaVita with a new price target

      Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

      3/6/24 8:09:27 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita upgraded by UBS with a new price target

      UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

      8/7/23 7:20:56 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously

      11/1/22 9:18:39 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Financials

    Live finance-specific insights

    See more
    • DaVita Inc. 1st Quarter 2025 Results

      DENVER, May 12, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2025. "Our strong first quarter performance demonstrates the stability and consistency of our operating model" said Javier Rodriguez, CEO of DaVita Inc. "We maintain a steadfast commitment to being the provider, employer and partner of choice and returning value to our shareholders." Financial and operating highlights for the quarter ended March 31, 2025: Consolidated revenues were $3.224 billion.Operating income was $439 million.Diluted earnings per share was $2.00.Operating cash flow was $180 million and free cash flow was $(45) million.Repurchased 3.7 milli

      5/12/25 4:05:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

      DENVER, April 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 12, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Monday, May 12, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the

      4/30/25 11:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. 4th Quarter 2024 Results

      DENVER, Feb. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended December 31, 2024. "Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range," said Javier Rodriquez, CEO of DaVita Inc. "As we embark on 2025, when we will be celebrating the 25th anniversary of DaVita, we look forward to continuing our efforts to improve clinical outcomes, enhance quality of life for our patients and teammates, and be a force for positive change in the healthcare system." Financial and operating highlights for the quarter and year ended Decembe

      2/13/25 4:05:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    SEC Filings

    See more
    • DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - DAVITA INC. (0000927066) (Filer)

      5/23/25 4:28:44 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - DAVITA INC. (0000927066) (Filer)

      5/20/25 4:58:28 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - DAVITA INC. (0000927066) (Filer)

      5/20/25 9:07:35 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care